A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 196,282 shares of ABBV stock, worth $34.5 Million. This represents 1.51% of its overall portfolio holdings.

Number of Shares
196,282
Previous 189,255 3.71%
Holding current value
$34.5 Million
Previous $32.5 Million 19.41%
% of portfolio
1.51%
Previous 1.34%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $1.15 Million - $1.4 Million
7,027 Added 3.71%
196,282 $38.8 Million
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $2.2 Million - $2.57 Million
14,220 Added 8.12%
189,255 $32.5 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $1.69 Million - $1.93 Million
-10,579 Reduced 5.7%
175,035 $31.9 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $134,435 - $151,405
-977 Reduced 0.52%
185,614 $28.8 Million
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $2.08 Million - $2.41 Million
15,578 Added 9.11%
186,591 $27.8 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $333,395 - $414,888
-2,516 Reduced 1.45%
171,013 $23 Million
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $5.03 Million - $5.79 Million
-34,776 Reduced 16.69%
173,529 $27.7 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $6.46 Million - $7.75 Million
46,728 Added 28.92%
208,305 $33.7 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $4.24 Million - $4.86 Million
31,598 Added 24.31%
161,577 $21.7 Million
Q2 2022

Aug 16, 2022

BUY
$137.62 - $174.96 $507,404 - $645,077
3,687 Added 2.92%
129,979 $19.9 Million
Q1 2022

May 17, 2022

BUY
$131.98 - $163.75 $4.74 Million - $5.88 Million
35,913 Added 39.74%
126,292 $20.5 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $29,006 - $36,701
-270 Reduced 0.3%
90,379 $12.2 Million
Q3 2021

Nov 12, 2021

SELL
$106.4 - $120.78 $9.82 Million - $11.1 Million
-92,265 Reduced 50.44%
90,649 $9.78 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $9.23 Million - $10.3 Million
87,774 Added 92.26%
182,914 $20.6 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $3.46 Million - $3.8 Million
33,784 Added 55.06%
95,140 $10.3 Million
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $263,765 - $356,111
3,277 Added 5.64%
61,356 $6.57 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $1.33 Million - $1.56 Million
-15,431 Reduced 20.99%
58,079 $5.09 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $1.15 Million - $1.53 Million
15,622 Added 26.99%
73,510 $7.22 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $822,246 - $1.25 Million
-12,748 Reduced 18.05%
57,888 $4.41 Million
Q4 2019

Feb 13, 2020

SELL
$72.13 - $90.25 $788,380 - $986,432
-10,930 Reduced 13.4%
70,636 $6.25 Million
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $478,899 - $575,774
7,604 Added 10.28%
81,566 $6.18 Million
Q2 2019

Aug 13, 2019

SELL
$65.7 - $83.98 $350,969 - $448,621
-5,342 Reduced 6.74%
73,962 $5.38 Million
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $128,052 - $150,711
-1,660 Reduced 2.05%
79,304 $6.39 Million
Q4 2018

Feb 12, 2019

SELL
$77.85 - $96.01 $61,735 - $76,135
-793 Reduced 0.97%
80,964 $7.46 Million
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $87,131 - $96,863
980 Added 1.21%
81,757 $7.73 Million
Q2 2018

Aug 13, 2018

BUY
$89.78 - $106.23 $638,335 - $755,295
7,110 Added 9.65%
80,777 $7.48 Million
Q1 2018

May 14, 2018

BUY
$92.01 - $123.21 $40,576 - $54,335
441 Added 0.6%
73,667 $6.97 Million
Q4 2017

Feb 13, 2018

SELL
$89.56 - $98.21 $418,961 - $459,426
-4,678 Reduced 6.0%
73,226 $7.08 Million
Q3 2017

Nov 08, 2017

BUY
$69.85 - $89.22 $5.44 Million - $6.95 Million
77,904
77,904 $6.92 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Meiji Yasuda Asset Management CO Ltd. Portfolio

Follow Meiji Yasuda Asset Management CO Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Asset Management CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Asset Management CO Ltd. with notifications on news.